Ropes & Gray Represents Accutar Biotechnology in Evommune AI Drug Discovery Collaboration

In The News
November 28, 2023

Ropes & Gray advised Accutar Biotechnology in a strategic partnership with Evommune focused on the discovery of novel small molecule drug candidates in chronic inflammatory diseases. The collaboration will leverage Accutar’s AI platform as well as Evommune’s experience in the design and development of oral small molecule therapies against targets that are the cause of chronic immune inflammatory diseases. The collaboration was announced on November 28. Financial terms were not disclosed.

Accutar is a clinical stage biotechnology company focused on AI-powered drug discovery. The company has a hybrid approach of computational drug design and wet lab validation.

The Ropes & Gray team included life sciences transactions partner Hannah England and intellectual property transactions associate Sameer Desai.